Neutra's VIVIS Excited to Release New Gummy!
Neutra Corp. (OTC PINK:NTRR) is advancing its Phase-1 clinical trials to evaluate the effectiveness of hemp-based cannabinoids, specifically CBDa, against COVID-19. Building on prior research from Oregon State University, which indicated that CBDa and CBGa could prevent the virus from entering human cells, Neutra aims to demonstrate these cannabinoids' safety and efficacy in combating the virus. Their subsidiary, VIVIS, has partnered with Mercury Clinical Research for these trials. Neutra is also launching a new gummy product infused with CBDa and CBGa, targeting COVID-related health issues.
- Neutra Corp. is conducting Phase-1 clinical trials for hemp-based cannabinoids CBDa and CBGa, aimed at preventing COVID-19 infection.
- The trials are based on promising findings from Oregon State University that cannabis compounds can inhibit coronavirus entry into human cells.
- The company anticipates that their new gummy product containing CBDa and CBGa will help address COVID-related health challenges.
- None.
KATY, TX / ACCESSWIRE / January 18, 2022 / Neutra Corp. (OTC PINK:NTRR) continues plans for Phase-1 clinical trials regarding the effectiveness of two hemp-based cannabinoids (CBDa) in stopping COVID-19 infection. The tests seek to build upon an earlier Oregon State University study published in the Journal of Nature Products that showed cannabis compounds cannabidiolic acid (CBDa) and cannabigerolic acid (CBGa) prevented the coronavirus from penetrating human cells. Bloomberg recently reported on the study and its results.
"We remain committed to these hemp-based CBD phase-1 clinical trials," said Neutra CEO Sydney Jim. "The earlier study showed great promise. I know it will take time to get started and but this is part of our plans for 2022. We are hopeful that our trials will show that hemp-based cannabinoid compounds to be a safe way to help to protect people from the coronavirus and SARS-CoV-2 that continues to plague the world after two years."
Neutra announced last September that its VIVIS subsidiary had signed a letter of intent with Mercury Clinical Research to pursue such trials. The main uses for CBD have been helping with inflammation, anxiety and sleep. The trials could also investigate additional hemp-based compound uses for anti-inflammation, anti-insomnia, appetite suppressant and stimulant (CBG vs. CBN), recovery, pain-management, anti-anxiety, and other health related diagnosis
CBDa and CBGa can be taken orally. Based on the published Oregon State study, VIVIS has developed a new gummy product containing the compounds. The company expects the gummy to help in the battle against COVID. CBDa can be used to combat inflammation, pain and nausea. CBGa may also be effective in fighting metabolic disorders and cardiovascular disease.
About Neutra Corp.
Neutra Corp. (OTC PINK:NTRR) is an early-stage research and development company with a focus on bringing modern healthy living solutions to a multibillion-dollar market. Cutting-edge technologies within the nutraceuticals, food, and drug, and environmental purification sectors are creating a new kind of world culture-one where in which consumers are demanding access to products that promote health and stave off potential health dangers. One of the nutraceutical sub-markets is the new thriving hemp-based CBD market, in which the Company intends to participate. For more information, visit the Company's website at http://www.NeutraInc.com.
NOTICE REGARDING FORWARD-LOOKING STATEMENTS
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words 'believes,' 'expects,' 'anticipate' or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results, performance, or achievements of the company to differ materially from those expressed or implied by such forward-looking statements.
Neutra Contact:
Sydney Jim
888-433-4033
info@neutrainc.com
SOURCE: Neutra Corp.
View source version on accesswire.com:
https://www.accesswire.com/683725/Neutras-VIVIS-Excited-to-Release-New-Gummy
FAQ
What is Neutra Corp's stock symbol?
What clinical trials is Neutra Corp. conducting?
What is the significance of the Oregon State University study for NTRR?
What product is Neutra Corp. launching related to COVID-19?
Who is collaborating with Neutra Corp. for the clinical trials?
